CSBio CSBio

X
[{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea\u00ae (Paclitaxel Micellar) in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inceptua Group"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe. These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland).

            Lead Product(s): Paclitaxel

            Therapeutic Area: Oncology Product Name: Apealea

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Elevar Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY